85 reports of this reaction
5.0% of all BIVALIRUDIN reports
#3 most reported adverse reaction
HAEMORRHAGE is the #3 most commonly reported adverse reaction for BIVALIRUDIN, manufactured by Accord Healthcare, Inc.. There are 85 FDA adverse event reports linking BIVALIRUDIN to HAEMORRHAGE. This represents approximately 5.0% of all 1,699 adverse event reports for this drug.
Patients taking BIVALIRUDIN who experience haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMORRHAGE is moderately reported among BIVALIRUDIN users, representing a notable but not dominant share of adverse events.
In addition to haemorrhage, the following adverse reactions have been reported for BIVALIRUDIN:
The following drugs have also been linked to haemorrhage in FDA adverse event reports:
HAEMORRHAGE has been reported as an adverse event in 85 FDA reports for BIVALIRUDIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMORRHAGE accounts for approximately 5.0% of all adverse event reports for BIVALIRUDIN, making it one of the most commonly reported side effect.
If you experience haemorrhage while taking BIVALIRUDIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.